• Autolus Therapeutics presented longer-term Phase 1 CARLYSLE results for obe-cel in severe refractory systemic lupus erythematosus at ACR Convergence 2026.
• Most participants achieved disease remission despite severe baseline disease; kidney responses were observed without severe renal flares.
• Obe-cel was well tolerated in 15 patients, with no severe cytokine release syndrome or specified neurological and inflammatory complications observed.
• Follow-up extended to 25 months in adults; the therapy is being evaluated in the Phase 2 LUMINA trial for lupus nephritis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Autolus Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611101605PRIMZONEFULLFEED9874314) on November 10, 2026, and is solely responsible for the information contained therein.